Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapaquistat Acetate Dosing Time in Hypercholesterolemia
NCT00865228Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jul 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lapaquistat in hypercholesterolemia (4 arms), sponsored by Takeda. Primary endpoint: Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration at Week 6. Started Jul 2007; status: terminated.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00865228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00865228.